日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

更正:Onvansertib联合FOLFIRI和贝伐单抗二线治疗KRAS突变转移性结直肠癌:一项Ib期临床研究

Ahn, Daniel H; Barzi, Afsaneh; Ridinger, Maya; Samuëlsz, Errin; Subramanian, Ramanand A; Croucher, Peter J P; Smeal, Tod; Kabbinavar, Fairooz F; Lenz, Heinz-Josef

Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer.

靶向 PLK1 可降低 MMP10 以增强 HPV 头颈癌的放射敏感性。

Korns Julianna, Lehn Maria A, Shyamsunder Shreya, Medvedovic Mario, Bryant Stephanie M, Sertorio Mathieu G, Ridinger Maya, Wise-Draper Trisha M, Takiar Vinita

An experiment on the impacts of experiential investment advice

一项关于体验式投资建议影响的实验

Ridinger, Garret; Sundali, James; Guerrero, Federico; Solorio, Mauricio; Fan, Mengyue; Sevindik, Irem; Chen, Qifan; Neely, Diana

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial

Onvansertib 联合化疗和贝伐单抗用于 KRAS 突变转移性结直肠癌的二线治疗:一项单组 II 期试验

Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr, Joleen M Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A Subramanian, Divora Yemane, Roy Kim, Chu-Chiao Wu, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz

Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas

在患者来源的铂类耐药卵巢癌中,以Onvansertib为基础的二线疗法联合吉西他滨和卡铂

Guffanti, Federica; Mengoli, Ilaria; Ricci, Francesca; Perotti, Ludovica; Capellini, Elena; Sala, Laura; Canesi, Simone; Wu, Chu-Chiao; Fruscio, Robert; Ridinger, Maya; Damia, Giovanna; Chiappa, Michela

PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia.

PLK1 抑制可导致范可尼贫血通路缺陷型急性髓系白血病发生合成致死

Sheth Aditya S, Chan Ka-Kui, Liu Sheng, Wan Jun, Angus Steve P, Rhodes Steven D, Mitchell Dana K, Davis Christopher, Ridinger Maya, Croucher Peter J, Zeidan Amer M, Wijeratne Aruna, Qian Shaomin, Tran Ngoc Tung, Sierra Potchanant Elizabeth A

Assessing shared decision-making: a case study of third-year medical student standardized patient encounters

评估共同决策:以三年级医学生标准化病人诊疗为例

Induru, Vikranth; Deffendall, Catherine; Theobald, Ceceila; Green, Jennifer; Ridinger, Heather

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Onvansertib 联合 FOLFIRI 和贝伐单抗用于 KRAS 突变转移性结直肠癌二线治疗:Ib 期临床研究

Daniel H Ahn #, Afsaneh Barzi #, Maya Ridinger #, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Onvansertib治疗克服了高级别卵巢癌的奥拉帕尼耐药性

Chiappa, Michela; Decio, Alessandra; Guarrera, Luca; Mengoli, Ilaria; Karki, Anju; Yemane, Divora; Ghilardi, Carmen; Scanziani, Eugenio; Canesi, Simone; Barbera, Maria C; Craparotta, Ilaria; Bolis, Marco; Fruscio, Robert; Grasselli, Chiara; Ceruti, Tommaso; Zucchetti, Massimo; Patterson, Jesse C; Lu, Robin A; Yaffe, Micheal B; Ridinger, Maya; Damia, Giovanna; Guffanti, Federica

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

AKT 抑制可增强前列腺癌患者对 Polo 样激酶 1 抑制剂 Onvansertib 的敏感性

Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L Dalrymple, Christopher M Dennehy, John T Isaacs, David J Einstein, W Nathaniel Brennen, Steven P Balk